Friday, 6 May 2022
Experts emphasise the importance of cooperation in sharing data on artemisinin resistance in Africa
Drug-resistant malaria is now a critical public health emergency on a global scale. In a new editorial a diverse group of malaria researchers, including WWARN senior scientists, have highlighted that the artemisinin confirmed recently in Rwanda and Uganda is likely just the ‘tip of the spear’, with ...
Tuesday, 29 March 2022
Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO
The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.
Monday, 28 March 2022
Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria
WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.
Friday, 18 March 2022
Sharing expertise with scientific collaborators in India
Last year, the Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO began collaborating on a joint capacity building venture to train young researchers across three infectious diseases.
Monday, 28 February 2022
ANTICOV trial finds drug combination nitazoxanide + ciclesonide does not reduce risk of hospitalization in COVID-19 outpatients
KINSHASA / NAIROBI / GENEVA – 28 February 2022 – The ANTICOV platform clinical trial, launched in September 2020 in 13 African countries to identify treatments for mild and moderate cases of COVID-19, has stopped recruiting patients into one of its treatment arms, the drug combination nitazoxanide a...
Thursday, 10 February 2022
ANTICOV: clinical trial for COVID-19 in low-resource settings to test a new combination treatment, fluoxetine and budesonide
KINSHASA / NAIROBI / GENEVA – 8 February 2022 – The ANTICOV platform clinical trial has started the recruitment of participants to test a new promising drug combination, fluoxetine and budesonide, as an early treatment for people affected with mild-to-moderate COVID-19.
Friday, 19 November 2021
Paul Newton named ASTMH Distinguished International Fellow
Professor Paul Newton was announced new Distinguished International Fellow at the ASTMH Annual Meeting Awards Ceremony on the 17th November. This distinction formally recognises individuals who have made eminent contributions to a particular aspect of tropical medicine or hygiene.
Thursday, 28 October 2021
Large-scale systematic review identifies research gaps in scrub typhus
A new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for chil...
Friday, 8 October 2021
Lack of evidence is key barrier to using portable devices to detect poor quality medicines
A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.
Tuesday, 21 September 2021
New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease
A new study suggests there are important but neglected issues with substandard and falsified (SF*) medicines and medical products used to prevent and treat cardiovascular diseases.
Monday, 20 September 2021
Open call to join new studies launched by the VL research community
Two new Study Groups, a collaboration between IDDO and the global visceral leishmaniasis (VL) research community, have been formed to answer specific research questions about treatments. They will undertake individual patient data meta-analyses using datasets from multiple studies, across sub-popula...